4.330GBp+0.70%Mkt Cap: 27.02M GBpP/E: —Last update: 2026-06-01
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeut…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap27.02M GBp
Enterprise Value21.09M GBp
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-2.48M GBp
Revenue/Share—
Last Price4.330 GBp
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees6
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB0033711010
Valuation
P/E (Trailing)—
P/E (Forward)-0.01
PEG—
EV/EBITDA-6.73
EV/Revenue—
P/S—
P/B43.00
EPS (TTM)0.00
EPS (Forward)-3.39
52W Range
1.38616% of range19.40
52W High19.40 GBp
52W Low1.386 GBp
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE457.49%
ROA-254.19%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.77M GBp
CapEx (TTM)1.65K GBp
FCF Margin—
FCF Yield-9.36%
Net Debt-396.65K GBp
Net Debt/EBITDA0.13
Balance Sheet
Debt/Equity—
Current Ratio1.21
Quick Ratio0.73
Book Value/Sh0.0010 GBp
Cash/Share0.0010 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.623.91M
Float484.15M
Insiders5.01%
Institutions19.39%
Technical
SMA 504.515 (-4.1%)
SMA 2007.166 (-39.6%)
Beta2.98
S&P 52W Chg27.94%
Avg Vol (30d)1.92M
Avg Vol (10d)1.56M
Technical Indicators
RSI (14)45.8
MACD-0.0806
MACD Signal-0.1162
MACD Hist.+0.0356
BB Upper4.692 GBp
BB Middle4.301 GBp
BB Lower3.910 GBp
BB Width18.16%
ATR (14)0.5626 GBp
Vol Ratio (20d)0.70x